Abrysvo vs. Arexvy: Key Differences, Side Effects, and Coverage

Respiratory syncytial virus (RSV) is a prevalent respiratory virus that often causes mild, cold-like symptoms but can lead to severe illness in infants and older adults. To address this health concern, two new vaccines, Abrysvo and Arexvy, are now available. These vaccines are designed to protect against RSV by enhancing the body’s immune response.

Table of contents

[hide]

Overview of Abrysvo and Arexvy

Both Abrysvo and Arexvy target RSV but have some distinct differences in their formulation and usage. Here’s a breakdown of what sets them apart:

Abrysvo vs. Arexvy: Key Differences

Abrysvo

Developed by: Pfizer Inc.
Type: Bivalent vaccine (protects against RSV A and RSV B)
Adjuvant: No adjuvant
Approval: Approved for use in pregnant women (32-36 weeks of pregnancy)
Efficacy: 67% efficacy in preventing RSV infections with at least two symptoms; 86% in preventing severe RSV illness in older adults.

Arexvy

Developed by: GlaxoSmithKline (GSK)
Type: Adjuvanted vaccine
Adjuvant: Yes
Approval: Not approved for pregnant women
Efficacy: 83% effective in preventing severe RSV infections; 72% in preventing acute RSV infections; reduced severe respiratory disease in newborns by 69%.

Conditions Treated

Both Abrysvo and Arexvy are used to prevent RSV-induced lower respiratory tract diseases, particularly in older adults. According to the CDC, adults aged 60 and older should receive a single dose of either vaccine in late summer or early fall. Notably, Abrysvo is recommended for pregnant women between 32 and 36 weeks to protect their newborns from severe respiratory diseases.

Insurance Coverage and Cost

Both Abrysvo and Arexvy are typically covered by insurance and eligible for Medicare Part D, which can minimize out-of-pocket expenses. Without insurance, the cost can vary. For instance, SingleCare lists the following prices:

Abrysvo: $300
Arexvy: $285

Side Effects

Common side effects for both vaccines include pain at the injection site, fatigue, muscle pain, and headache. Abrysvo may also cause nausea and diarrhea, whereas Arexvy does not.

Comparison of Side Effects

Injection site pain: 40% for Abrysvo, 61% for Arexvy
Fatigue: 16% for Abrysvo, 34% for Arexvy
Nausea: 20% for Abrysvo, not reported for Arexvy

Drug Interactions and Warnings

Neither vaccine has reported significant drug interactions, but immunosuppressant drugs may affect their efficacy. Abrysvo is associated with a risk of premature birth if administered to pregnant women outside the recommended period. Both vaccines can cause severe allergic reactions, so monitoring by a healthcare provider post-vaccination is essential.

Related

Conclusion

Both Abrysvo and Arexvy offer effective protection against RSV, with each having unique benefits and considerations. When choosing between these vaccines, it’s important to consult with a healthcare provider to determine which is best suited for your individual health needs and circumstances.

Consult a healthcare provider to find the most appropriate RSV vaccine for you.

Abrysvo vs. Arexvy: Differences, similarities & side effects